Abstract | OBJECTIVES: METHODS: Thirty-three patients with MTC received vandetanib (n = 23) or placebo (n = 10) in the ZETA study. Visceral AT (VAT), sc AT (SAT), and SM were assessed with computed tomography imaging by measuring tissue cross-sectional areas (square centimers per square meter). Dose-limiting toxicities (DLTs) were prospectively recorded. RESULTS: Early at 3 months, compared with placebo group who lost BW, muscle, and SAT, patients treated with vandetanib gained 1.5 kg BW (P = 0.02), 1.3 cm(2)/m(2) (∼0.7 kg) of SM (P = 0.009), and 4.5 cm(2)/m(2) (∼0.5 kg) of SAT (P = 0.004) and gained more VAT, 5.1 cm(2)/m(2) (∼0.7 kg) (P = 0.02). Patients with DLT had lower SM index (37.2 vs 44.3 cm(2)/m(2), P = 0.003) and a higher vandetanib serum concentration (1091 vs 739 ng/mL, P = 0.03). Patients with SM index <43.1 cm(2)/m(2) had a higher probability of DLT (73% vs 14%, P = 0.004) and a higher vandetanib serum concentration (1037 vs 745 ng/mL, P = 0.04). Patients with the highest compared with the intermediate and lower levels of vandetanib serum concentration experienced more DLT, respectively, 78% vs 40% vs 20% (P = 0.04). CONCLUSIONS: Muscle and adipose tissues are restored after only 3 months of vandetanib treatment. Patients with low muscle mass had high vandetanib serum concentration and high incidence of toxicities.
|
Authors | Marie-Hélène Massicotte, Isabelle Borget, Sophie Broutin, Vickie E Baracos, Sophie Leboulleux, Eric Baudin, Angelo Paci, Alain Deroussent, Martin Schlumberger, Sami Antoun |
Journal | The Journal of clinical endocrinology and metabolism
(J Clin Endocrinol Metab)
Vol. 98
Issue 6
Pg. 2401-8
(Jun 2013)
ISSN: 1945-7197 [Electronic] United States |
PMID | 23543666
(Publication Type: Controlled Clinical Trial, Journal Article)
|
Chemical References |
- Piperidines
- Protein Kinase Inhibitors
- Quinazolines
- vandetanib
|
Topics |
- Adult
- Aged
- Body Composition
- Carcinoma, Neuroendocrine
- Cross-Over Studies
- Female
- Humans
- Male
- Middle Aged
- Muscle, Skeletal
(metabolism)
- Piperidines
(adverse effects, blood, therapeutic use)
- Protein Kinase Inhibitors
(therapeutic use)
- Quinazolines
(adverse effects, blood, therapeutic use)
- Thyroid Neoplasms
(drug therapy, metabolism)
|